Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine

• 主要な著者: Daniel Cowley (著者), Karen Boniface (著者), Nada Bogdanovic-Sakran (著者), Carl D. Kirkwood (著者), Julie E. Bines (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2017-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0-5 d ol...